Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo Bio CoTSE:3386 +1.12%73 5-Year Yield-on-Cost % is 9.28 as of Aug. 04, 2026, which is 147% above its 10-year median of 3.75. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,251.05 (Fairly Valued). The stock has 4 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 82.54% on this metric.
Cosmo Bio Co's yield on cost for the quarter that ended in Dec. 2025 was 9.28.
The historical rank and industry rank for Cosmo Bio Co's 5-Year Yield-on-Cost % or its related term are showing as below:
TSE:3386'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.02 Med: 3.75 Max: 11.15
Current: 9.28
During the past 13 years, Cosmo Bio Co's highest Yield on Cost was 11.15. The lowest was 2.02. And the median was 3.75.
TSE:3386's 5-Year Yield-on-Cost % is ranked better than 82.54% of 63
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.48
vs TSE:3386: 9.28
Cosmo Bio Co (TSE:3386) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Cosmo Bio Co 5-Year Yield-on-Cost % Related Terms
TSE:3386 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Cosmo Bio Co is calculated as
Cosmo Bio Co (TSE:3386) has a 5-Year Yield-on-Cost % of 9.28 as of Aug. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cosmo Bio Co and its competitors. This is 147% above median its historical median of 3.75. Over the past decade, Cosmo Bio Co's 5-Year Yield-on-Cost % has ranged from 2.02 to 11.15. According to the industry distribution chart, Cosmo Bio Co ranks #11 out of 63 companies in the Medical Diagnostics & Research industry, placing it in the top 17.5%.
Is Cosmo Bio Co's 5-Year Yield-on-Cost % too high?
Cosmo Bio Co's current 5-Year Yield-on-Cost % of 9.28 is 147% above median its 10-year median of 3.75. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 11.15. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.48. Cosmo Bio Co's value of 9.28 is 274.2% above this industry median. Based on the distribution chart, Cosmo Bio Co ranks #11 out of 63 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #11 out of 63 companies for 5-Year Yield-on-Cost %. This places Cosmo Bio Co in the top 18% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.48. Cosmo Bio Co's value of 9.28 is 274.2% above this benchmark. Historically, Cosmo Bio Co's own 5-Year Yield-on-Cost % has ranged from 2.02 to 11.15 over the past decade. While the company's 10-year median is 3.75 vs. the industry median of 2.48, Cosmo Bio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.48, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo Bio Co's current 5-Year Yield-on-Cost % of 9.28 is 274.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cosmo Bio Co and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo Bio Co's current 5-Year Yield-on-Cost % is 9.28, which is 147% above median its own 10-year median of 3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,251.05, compared to a current price of 円1,266.00 — trading 1.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 9.28, which is 147% above median its 10-year median of 3.75 and 274.2% above the Medical Diagnostics & Research industry median of 2.48. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current 5-Year Yield-on-Cost % is 9.28 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,266.00 is trading 1.2% above its estimated GF Value™ of 円1,251.05.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
5-Year Yield-on-Cost %: 9.28 (147% above median its 10-year median of 3.75)
GF Value™: 円1,251.05 vs. price of 円1,266.00 (1.2% above fair value)
Industry Position: 274.2% above the Medical Diagnostics & Research median (#11 of 63)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
